by TractManager | Nov 21, 2023 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of systemic (chamber) hyperbaric oxygen therapy (HBOT) for the treatment of venous ulcers for improved wound closure...
by TractManager | Nov 16, 2023 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of the miraDry system (miraDry Inc.) in adult patients with primary axillary hyperhidrosis (PAH) for reduced sweat...
by TractManager | Nov 16, 2023 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of topical (local) hyperbaric oxygen therapy (HBOT) for the treatment of venous ulcers to improve wound...
by TractManager | Nov 16, 2023 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of percutaneous sacroplasty for the treatment of sacral insufficiency fractures (SIFs) in adults who primarily have...
by TractManager | Nov 16, 2023 | Emerging Technology Report
Adzynma (Takeda Pharmaceutical Co. Ltd.) is a human recombinant “A disintegrin and metalloproteinase with thrombospondin motifs 13” (rADAMTS13) indicated for prophylactic or on demand enzyme replacement therapy in adult and pediatric patients with congenital...
Recent Comments